Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representative(s) of Baring Private Equity Asia, would be having meeting with us at 3.30 P.M. on Friday, July 05, 2019, at the Corporate Office of the Company, followed by a visit to our Lab. Please note that this meeting is subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
This is to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with immediate effect, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2019. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the following forthcoming Analyst Meetings to be held at the Corporate Office of the Company: i) Meeting with the representative(s) of PhillipCapital India Private Limited, at 3.30 P.M. on Wednesday, July 03, 2019. ii) Meeting with the representative(s) of Centrum Capital Ltd., at 4.30 P.M. on Friday, July 05, 2019. Please note that these meetings are subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith a transcript of the conference call held on Tuesday, May 21, 2019 at 04.00 P.M. local time, to discuss the Company's Audited financial results (Stand-alone and Consolidated) for the year ended March 31, 2019. Dr. Velumani A., Ph.D., CEO, Mr. A. Sundararaju, CFO, Mr. Sachin Salvi, Vice-President- Finance and Dr. Caesar Sengupta, Vice-President- Operations, represented the Company. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the following forthcoming Analyst Meetings to be held at the Corporate Office of the Company: i) Meeting with the representative(s) of Securities Investment Management Pvt. Ltd., at 3.30 P.M. on Wednesday, June 26, 2019. ii) Meeting with the representative(s) of HDFC Securities Limited, at 4.30 P.M. on Wednesday, June 26, 2019. Please note that these meetings are subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Disclosure Of Related Party Transactions For The Half Year Ended 31-03-2019
Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are filing herewith Disclosure of Related Party Transactions during the half year ended on March 31, 2019 on a consolidated basis, in the format specified in the accounting standards, and the same is also available on the website of the Company viz, www.thyrocare.com. Thyrocare Technologies Ltd - 539871 - Outcome of Board Meeting
Please refer to our letter dated 20-05-2019, intimating that at the Board Meeting on 18-05-2019, when Auditors pointed out impairment of investment in Nueclear Healthcare Limited (NHL), wholly owned subsidiary, Dr.A.Velumani, Chairman, MD & CEO offered to buy Company's entire shareholding in NHL at the current investment value of Rs. 194.67 crores to ensure that there is no loss to the public shareholders. This offer was discussed today by Audit Committee and Board. Both Audit Committee and Board have unanimously decided that Company has to determine whether it would be beneficial to hive off the subsidiary or retain it, and for this purpose, it would be advisable to obtain one more valuation report to ensure that the valuation of the subsidiary is correctly ascertained. The Committee decided to appoint a SEBI approved merchant banker to submit a valuation report in the shortest possible time and then take a decision. None of the Promoter-directors were present during the discussions. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you about the following forthcoming Analyst Meetings to be held at the Corporate Office of the Company: i) Meeting with the representative(s) of Sundaram Mutual Fund, at 10.30 A.M. on Saturday, June 15, 2019. ii) Meeting with the representative(s) of Reliance Mutual Fund, at 12.00 Noon on Saturday, June 15, 2019. iii) Meeting with the representative(s) of Banyan Capital Advisors LLP, at 10.00 A.M. on Wednesday, June 19, 2019. iv) Meeting with the representative(s) of Grandeur Peak Global Advisors, at 02.00 P.M. on Thursday, June 27, 2019. Please note that these meetings are subject to any last minute changes. Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Discussing The Offer Made By Dr.A. Velumani, Chairman, Managing Director & CEO, To Acquire The Shareholding Of The Company In Nueclear Healthcare Limited, The Wholly Owned Subsidiary Of The Company.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/06/2019 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors will be held on Thursday, June 13, 2019, to discuss about the offer made by Dr. A. Velumani, Chairman, Managing Director & CEO to acquire the shareholding of the Company in Nueclear Healthcare Limited (NHL), the wholly owned subsidiary of the Company.